 Douglas Seals
Concepts (763)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 199 | 2025 | 1864 | 21.460 |
Why?
| | Endothelium, Vascular | 86 | 2025 | 927 | 15.580 |
Why?
| | Vascular Stiffness | 45 | 2025 | 494 | 9.530 |
Why?
| | Oxidative Stress | 65 | 2025 | 1317 | 8.470 |
Why?
| | Exercise | 102 | 2025 | 2057 | 8.240 |
Why?
| | Vasodilation | 62 | 2025 | 499 | 8.030 |
Why?
| | Arteries | 33 | 2024 | 269 | 6.590 |
Why?
| | Brachial Artery | 40 | 2025 | 205 | 6.400 |
Why?
| | Sympathetic Nervous System | 68 | 2025 | 182 | 6.340 |
Why?
| | Blood Pressure | 105 | 2025 | 1786 | 6.070 |
Why?
| | Writing | 8 | 2024 | 95 | 4.710 |
Why?
| | Biomedical Research | 11 | 2024 | 692 | 4.470 |
Why?
| | Carotid Arteries | 28 | 2024 | 206 | 4.270 |
Why?
| | Aorta | 19 | 2025 | 417 | 4.000 |
Why?
| | Vascular Diseases | 15 | 2023 | 243 | 3.740 |
Why?
| | Antioxidants | 24 | 2023 | 584 | 3.400 |
Why?
| | Regional Blood Flow | 36 | 2020 | 474 | 3.320 |
Why?
| | Nitric Oxide | 33 | 2023 | 915 | 3.320 |
Why?
| | Cardiovascular Diseases | 29 | 2025 | 2111 | 3.180 |
Why?
| | Physiology | 5 | 2024 | 15 | 3.110 |
Why?
| | Physical Endurance | 48 | 2016 | 275 | 3.090 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 3.030 |
Why?
| | Heart Rate | 84 | 2023 | 822 | 3.000 |
Why?
| | Publishing | 5 | 2023 | 147 | 2.990 |
Why?
| | Endothelial Cells | 21 | 2025 | 785 | 2.800 |
Why?
| | Postmenopause | 27 | 2025 | 366 | 2.800 |
Why?
| | Resistance Training | 5 | 2023 | 164 | 2.730 |
Why?
| | Aged | 179 | 2025 | 23961 | 2.690 |
Why?
| | Hypertension | 24 | 2025 | 1295 | 2.560 |
Why?
| | Dietary Supplements | 20 | 2025 | 561 | 2.440 |
Why?
| | Mitochondria | 10 | 2025 | 948 | 2.420 |
Why?
| | Caloric Restriction | 10 | 2021 | 124 | 2.390 |
Why?
| | Blood Vessels | 6 | 2020 | 187 | 2.380 |
Why?
| | Middle Aged | 200 | 2025 | 33479 | 2.340 |
Why?
| | Physical Exertion | 34 | 2014 | 215 | 2.260 |
Why?
| | Pulse Wave Analysis | 23 | 2025 | 272 | 2.240 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 36 | 2.220 |
Why?
| | Male | 261 | 2025 | 67762 | 2.110 |
Why?
| | Inflammation | 24 | 2024 | 2837 | 2.090 |
Why?
| | Humans | 349 | 2025 | 137585 | 2.070 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 204 | 2.070 |
Why?
| | Exercise Tolerance | 9 | 2025 | 279 | 2.060 |
Why?
| | Muscles | 32 | 2023 | 326 | 2.020 |
Why?
| | Ascorbic Acid | 17 | 2025 | 177 | 2.010 |
Why?
| | Physical Fitness | 20 | 2013 | 209 | 2.010 |
Why?
| | Baroreflex | 16 | 2016 | 57 | 1.980 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 257 | 1.920 |
Why?
| | Oxygen Consumption | 47 | 2023 | 696 | 1.920 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 42 | 1.910 |
Why?
| | NF-kappa B | 9 | 2015 | 691 | 1.880 |
Why?
| | Methylamines | 5 | 2022 | 34 | 1.870 |
Why?
| | Superoxides | 16 | 2022 | 202 | 1.860 |
Why?
| | Peer Review | 4 | 2023 | 49 | 1.850 |
Why?
| | Vasodilator Agents | 12 | 2024 | 331 | 1.810 |
Why?
| | Acetylcholine | 12 | 2023 | 185 | 1.720 |
Why?
| | Cellular Senescence | 8 | 2025 | 189 | 1.650 |
Why?
| | Norepinephrine | 29 | 2011 | 204 | 1.600 |
Why?
| | Adult | 203 | 2025 | 37929 | 1.580 |
Why?
| | Animals | 85 | 2025 | 36940 | 1.580 |
Why?
| | Mice | 54 | 2025 | 17787 | 1.560 |
Why?
| | Diet, Western | 3 | 2022 | 81 | 1.550 |
Why?
| | Female | 180 | 2025 | 73304 | 1.520 |
Why?
| | Heart | 16 | 2018 | 655 | 1.510 |
Why?
| | Healthy Aging | 4 | 2024 | 35 | 1.470 |
Why?
| | Adipose Tissue | 19 | 2018 | 635 | 1.470 |
Why?
| | Vascular Resistance | 20 | 2012 | 375 | 1.410 |
Why?
| | Mice, Inbred C57BL | 28 | 2025 | 5757 | 1.360 |
Why?
| | Motor Activity | 8 | 2024 | 718 | 1.360 |
Why?
| | Respiratory Muscles | 5 | 2023 | 33 | 1.350 |
Why?
| | Salicylates | 5 | 2015 | 28 | 1.350 |
Why?
| | Forearm | 18 | 2023 | 119 | 1.340 |
Why?
| | NADPH Oxidases | 13 | 2020 | 113 | 1.320 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 75 | 1.250 |
Why?
| | Research Personnel | 4 | 2023 | 173 | 1.240 |
Why?
| | Age Factors | 29 | 2025 | 3295 | 1.200 |
Why?
| | Muscle, Skeletal | 23 | 2025 | 1724 | 1.200 |
Why?
| | Reactive Oxygen Species | 14 | 2025 | 622 | 1.200 |
Why?
| | Double-Blind Method | 17 | 2025 | 1993 | 1.190 |
Why?
| | Estrogens | 8 | 2023 | 367 | 1.170 |
Why?
| | Tyrosine | 14 | 2020 | 222 | 1.150 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 34 | 1.140 |
Why?
| | Vasoconstriction | 7 | 2017 | 202 | 1.130 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 267 | 1.090 |
Why?
| | Femoral Artery | 11 | 2013 | 179 | 1.080 |
Why?
| | NAD | 5 | 2023 | 77 | 1.060 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 1.040 |
Why?
| | Geriatrics | 4 | 2015 | 98 | 1.040 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 1.030 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 146 | 1.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 350 | 1.010 |
Why?
| | Inflammation Mediators | 6 | 2025 | 513 | 1.000 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 127 | 0.960 |
Why?
| | Metabolomics | 4 | 2021 | 678 | 0.940 |
Why?
| | Longevity | 4 | 2015 | 165 | 0.940 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 29 | 0.910 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 4 | 0.900 |
Why?
| | Interleukin-1 | 5 | 2022 | 965 | 0.900 |
Why?
| | Curcumin | 2 | 2017 | 29 | 0.900 |
Why?
| | Elasticity | 11 | 2017 | 197 | 0.900 |
Why?
| | Drinking Water | 2 | 2022 | 84 | 0.890 |
Why?
| | Cross-Over Studies | 10 | 2023 | 564 | 0.870 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.870 |
Why?
| | Habits | 7 | 2017 | 49 | 0.870 |
Why?
| | Niacinamide | 4 | 2025 | 82 | 0.860 |
Why?
| | Doxorubicin | 3 | 2025 | 362 | 0.860 |
Why?
| | Trehalose | 4 | 2017 | 32 | 0.840 |
Why?
| | Career Choice | 2 | 2024 | 219 | 0.840 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 697 | 0.830 |
Why?
| | Body Composition | 30 | 2012 | 684 | 0.830 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 97 | 0.820 |
Why?
| | Physical Education and Training | 15 | 2024 | 76 | 0.820 |
Why?
| | Compliance | 15 | 2017 | 49 | 0.820 |
Why?
| | Fenofibrate | 2 | 2013 | 28 | 0.800 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 107 | 0.800 |
Why?
| | Goals | 1 | 2024 | 170 | 0.790 |
Why?
| | Elastin | 6 | 2023 | 78 | 0.790 |
Why?
| | Vaping | 1 | 2023 | 60 | 0.790 |
Why?
| | Young Adult | 29 | 2025 | 13209 | 0.780 |
Why?
| | Cardiorespiratory Fitness | 2 | 2021 | 55 | 0.780 |
Why?
| | Lyases | 1 | 2022 | 12 | 0.780 |
Why?
| | Transcriptome | 3 | 2023 | 971 | 0.780 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.770 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 91 | 0.770 |
Why?
| | Sodium, Dietary | 4 | 2013 | 41 | 0.770 |
Why?
| | Muscle Strength | 6 | 2023 | 317 | 0.760 |
Why?
| | Rest | 13 | 2007 | 121 | 0.750 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 103 | 0.750 |
Why?
| | Speech | 1 | 2022 | 70 | 0.740 |
Why?
| | Obesity | 14 | 2023 | 2992 | 0.740 |
Why?
| | Hemodynamics | 17 | 2023 | 1113 | 0.740 |
Why?
| | Research Design | 4 | 2022 | 1139 | 0.740 |
Why?
| | Stress, Physiological | 12 | 2017 | 443 | 0.740 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.730 |
Why?
| | Vagus Nerve | 7 | 2005 | 86 | 0.730 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.720 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.720 |
Why?
| | Leg | 14 | 2007 | 236 | 0.720 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.720 |
Why?
| | Spin Labels | 8 | 2020 | 48 | 0.710 |
Why?
| | Models, Animal | 6 | 2024 | 384 | 0.710 |
Why?
| | Running | 16 | 2017 | 230 | 0.700 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1242 | 0.690 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 346 | 0.680 |
Why?
| | Reference Values | 26 | 2021 | 816 | 0.680 |
Why?
| | Autophagy | 3 | 2017 | 284 | 0.680 |
Why?
| | Isometric Contraction | 14 | 1996 | 188 | 0.680 |
Why?
| | Comprehension | 1 | 2022 | 172 | 0.680 |
Why?
| | Cardiac Output | 15 | 2004 | 165 | 0.670 |
Why?
| | Biomarkers | 19 | 2025 | 4149 | 0.670 |
Why?
| | Frailty | 2 | 2024 | 170 | 0.670 |
Why?
| | Life Style | 14 | 2017 | 490 | 0.660 |
Why?
| | Cytokines | 10 | 2019 | 2085 | 0.660 |
Why?
| | Fasting | 2 | 2020 | 281 | 0.660 |
Why?
| | Nitroglycerin | 3 | 2020 | 17 | 0.650 |
Why?
| | Dementia | 1 | 2023 | 259 | 0.640 |
Why?
| | Nitrites | 3 | 2014 | 84 | 0.620 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2025 | 617 | 0.620 |
Why?
| | Spermidine | 2 | 2024 | 19 | 0.620 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 41 | 0.620 |
Why?
| | Overweight | 3 | 2009 | 558 | 0.610 |
Why?
| | Isoproterenol | 4 | 2007 | 113 | 0.610 |
Why?
| | Cardiovascular System | 10 | 2020 | 137 | 0.600 |
Why?
| | Sex Characteristics | 13 | 2011 | 762 | 0.600 |
Why?
| | Adolescent | 46 | 2023 | 21513 | 0.600 |
Why?
| | Sirtuin 1 | 3 | 2016 | 30 | 0.590 |
Why?
| | Lipids | 6 | 2018 | 672 | 0.590 |
Why?
| | Energy Metabolism | 9 | 2007 | 922 | 0.590 |
Why?
| | Mentoring | 1 | 2021 | 149 | 0.590 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 134 | 0.590 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 553 | 0.580 |
Why?
| | Amino Acids | 2 | 2019 | 497 | 0.570 |
Why?
| | Health Status | 3 | 2019 | 792 | 0.570 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 116 | 0.560 |
Why?
| | Blood Volume | 8 | 1998 | 61 | 0.560 |
Why?
| | Body Constitution | 4 | 2005 | 55 | 0.560 |
Why?
| | Glycation End Products, Advanced | 3 | 2013 | 82 | 0.550 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 36 | 0.550 |
Why?
| | Tunica Intima | 7 | 2006 | 84 | 0.540 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 446 | 0.540 |
Why?
| | Nitroprusside | 5 | 2011 | 69 | 0.540 |
Why?
| | Epinephrine | 14 | 2007 | 139 | 0.530 |
Why?
| | Diet | 6 | 2024 | 1278 | 0.530 |
Why?
| | Serine | 2 | 2015 | 141 | 0.520 |
Why?
| | Extracellular Matrix | 1 | 2021 | 528 | 0.520 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2189 | 0.510 |
Why?
| | Glucose | 4 | 2019 | 1020 | 0.510 |
Why?
| | Basal Metabolism | 4 | 2004 | 61 | 0.510 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 87 | 0.510 |
Why?
| | Diet Therapy | 1 | 2016 | 37 | 0.510 |
Why?
| | Cognition | 3 | 2025 | 1153 | 0.510 |
Why?
| | Muscle Contraction | 13 | 2003 | 424 | 0.510 |
Why?
| | Primary Prevention | 1 | 2018 | 196 | 0.500 |
Why?
| | Time Factors | 21 | 2021 | 6828 | 0.500 |
Why?
| | Exercise Therapy | 8 | 2025 | 443 | 0.490 |
Why?
| | Estradiol | 3 | 2021 | 521 | 0.480 |
Why?
| | Premenopause | 9 | 2025 | 131 | 0.480 |
Why?
| | Blood Glucose | 10 | 2017 | 2186 | 0.460 |
Why?
| | Cross-Sectional Studies | 22 | 2020 | 5472 | 0.460 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 20 | 0.450 |
Why?
| | Hand Strength | 4 | 2025 | 123 | 0.450 |
Why?
| | Collagen | 3 | 2021 | 452 | 0.450 |
Why?
| | Reflex | 6 | 2001 | 68 | 0.450 |
Why?
| | Body Mass Index | 18 | 2015 | 2389 | 0.450 |
Why?
| | Flavonols | 2 | 2025 | 18 | 0.450 |
Why?
| | Risk Factors | 19 | 2021 | 10388 | 0.450 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 197 | 0.440 |
Why?
| | Endothelium | 1 | 2014 | 123 | 0.440 |
Why?
| | Ubiquinone | 1 | 2014 | 29 | 0.440 |
Why?
| | Geriatric Assessment | 2 | 2015 | 224 | 0.430 |
Why?
| | Nitrates | 4 | 2022 | 92 | 0.430 |
Why?
| | Niacin | 1 | 2013 | 17 | 0.430 |
Why?
| | Proteome | 1 | 2018 | 472 | 0.420 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.420 |
Why?
| | Hindlimb | 1 | 2014 | 128 | 0.420 |
Why?
| | Atherosclerosis | 1 | 2018 | 415 | 0.420 |
Why?
| | Vitamin B Complex | 1 | 2013 | 44 | 0.420 |
Why?
| | Organophosphorus Compounds | 1 | 2014 | 78 | 0.410 |
Why?
| | Locomotion | 1 | 2014 | 106 | 0.410 |
Why?
| | Eating | 2 | 2007 | 380 | 0.410 |
Why?
| | Aortic Diseases | 1 | 2014 | 119 | 0.400 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 220 | 0.400 |
Why?
| | Exercise Test | 12 | 2021 | 625 | 0.390 |
Why?
| | Arm | 7 | 2008 | 104 | 0.390 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.390 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 7 | 0.390 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 113 | 0.390 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 64 | 0.380 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 48 | 0.380 |
Why?
| | Allopurinol | 2 | 2016 | 63 | 0.380 |
Why?
| | Pressoreceptors | 6 | 2001 | 19 | 0.370 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 2057 | 0.370 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 81 | 0.360 |
Why?
| | Postural Balance | 1 | 2014 | 215 | 0.360 |
Why?
| | Adrenal Glands | 3 | 2000 | 78 | 0.360 |
Why?
| | Arteritis | 1 | 2011 | 28 | 0.350 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 135 | 0.350 |
Why?
| | C-Reactive Protein | 3 | 2022 | 410 | 0.350 |
Why?
| | Ultrasonography | 11 | 2017 | 759 | 0.350 |
Why?
| | Oxidants | 1 | 2011 | 111 | 0.340 |
Why?
| | Systole | 6 | 2020 | 189 | 0.340 |
Why?
| | Uric Acid | 1 | 2012 | 163 | 0.340 |
Why?
| | Behavior, Animal | 1 | 2014 | 501 | 0.340 |
Why?
| | Colorado | 6 | 2024 | 4565 | 0.340 |
Why?
| | Pilot Projects | 5 | 2025 | 1710 | 0.340 |
Why?
| | Athletic Performance | 2 | 2012 | 79 | 0.340 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 365 | 0.330 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 191 | 0.330 |
Why?
| | Analysis of Variance | 7 | 2011 | 1316 | 0.320 |
Why?
| | Athletes | 2 | 2022 | 423 | 0.320 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 165 | 0.320 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2129 | 0.320 |
Why?
| | Metabolome | 3 | 2018 | 350 | 0.310 |
Why?
| | Peroxidase | 1 | 2010 | 175 | 0.310 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 45 | 0.310 |
Why?
| | Hot Temperature | 5 | 1993 | 391 | 0.310 |
Why?
| | Interleukins | 2 | 2022 | 250 | 0.310 |
Why?
| | Extremities | 2 | 2001 | 131 | 0.310 |
Why?
| | Blood Circulation | 4 | 2021 | 41 | 0.300 |
Why?
| | Biological Availability | 4 | 2021 | 148 | 0.300 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.300 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 243 | 0.300 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1809 | 0.290 |
Why?
| | Administration, Oral | 5 | 2015 | 816 | 0.290 |
Why?
| | Vitamin D | 2 | 2017 | 397 | 0.290 |
Why?
| | Healthy Volunteers | 3 | 2018 | 199 | 0.290 |
Why?
| | Oxygen | 11 | 2022 | 931 | 0.290 |
Why?
| | Interleukin-6 | 4 | 2024 | 778 | 0.290 |
Why?
| | Cells, Cultured | 5 | 2025 | 4193 | 0.290 |
Why?
| | Energy Intake | 6 | 2020 | 485 | 0.290 |
Why?
| | Endothelin-1 | 2 | 2009 | 182 | 0.290 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 48 | 0.290 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 48 | 0.290 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 558 | 0.290 |
Why?
| | Kidney | 7 | 2025 | 1468 | 0.290 |
Why?
| | Upper Extremity | 1 | 2009 | 99 | 0.290 |
Why?
| | Collagen Type I | 3 | 2014 | 136 | 0.290 |
Why?
| | Peroneal Nerve | 5 | 2000 | 19 | 0.290 |
Why?
| | Cognitive Dysfunction | 2 | 2025 | 383 | 0.290 |
Why?
| | Signal Transduction | 6 | 2014 | 5079 | 0.290 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 534 | 0.290 |
Why?
| | Posture | 6 | 2001 | 185 | 0.290 |
Why?
| | Abdomen | 5 | 2004 | 125 | 0.280 |
Why?
| | Hypercapnia | 2 | 2025 | 53 | 0.280 |
Why?
| | Sports | 5 | 2003 | 231 | 0.280 |
Why?
| | Phosphorylation | 6 | 2013 | 1759 | 0.270 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 413 | 0.270 |
Why?
| | Treatment Outcome | 7 | 2025 | 10811 | 0.270 |
Why?
| | Adiposity | 1 | 2012 | 518 | 0.270 |
Why?
| | Human Experimentation | 1 | 2007 | 13 | 0.270 |
Why?
| | Regression Analysis | 10 | 2011 | 1024 | 0.270 |
Why?
| | Acetophenones | 3 | 2019 | 13 | 0.270 |
Why?
| | Trimethaphan | 5 | 2005 | 5 | 0.270 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 840 | 0.260 |
Why?
| | Phenylephrine | 5 | 2005 | 75 | 0.260 |
Why?
| | Electrocardiography | 9 | 2005 | 629 | 0.260 |
Why?
| | Swimming | 5 | 2002 | 51 | 0.260 |
Why?
| | Tunica Media | 3 | 2001 | 38 | 0.260 |
Why?
| | Hypoxia | 6 | 1999 | 1112 | 0.260 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 240 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2607 | 0.250 |
Why?
| | Proteins | 3 | 2009 | 1009 | 0.250 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 545 | 0.250 |
Why?
| | Fatty Acids | 2 | 2019 | 443 | 0.250 |
Why?
| | Brain | 6 | 2023 | 2668 | 0.240 |
Why?
| | Microcirculation | 2 | 2019 | 149 | 0.240 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 283 | 0.240 |
Why?
| | Recovery of Function | 4 | 2017 | 653 | 0.240 |
Why?
| | Thermogenesis | 1 | 2005 | 44 | 0.240 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 45 | 0.230 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 26 | 0.230 |
Why?
| | Cell Nucleus | 1 | 2008 | 620 | 0.230 |
Why?
| | Carbon Dioxide | 3 | 2023 | 267 | 0.230 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 39 | 0.230 |
Why?
| | Flavonoids | 1 | 2025 | 85 | 0.230 |
Why?
| | Arginine | 1 | 2006 | 271 | 0.230 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 42 | 0.230 |
Why?
| | MicroRNAs | 1 | 2011 | 692 | 0.230 |
Why?
| | American Heart Association | 2 | 2020 | 306 | 0.230 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2025 | 127 | 0.230 |
Why?
| | Preventive Medicine | 2 | 2015 | 42 | 0.220 |
Why?
| | Acidosis | 1 | 2025 | 101 | 0.220 |
Why?
| | Veins | 5 | 2009 | 63 | 0.220 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.220 |
Why?
| | Aged, 80 and over | 13 | 2025 | 7635 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2025 | 3556 | 0.210 |
Why?
| | Skin | 4 | 2019 | 752 | 0.210 |
Why?
| | Respiratory Therapy | 1 | 2023 | 23 | 0.210 |
Why?
| | Weight Loss | 2 | 2008 | 787 | 0.210 |
Why?
| | Lactates | 7 | 2007 | 85 | 0.210 |
Why?
| | History, 21st Century | 1 | 2024 | 213 | 0.210 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 81 | 0.200 |
Why?
| | Blueberry Plants | 1 | 2023 | 7 | 0.200 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 78 | 0.200 |
Why?
| | Pyridinium Compounds | 2 | 2025 | 28 | 0.200 |
Why?
| | Hand | 8 | 1994 | 156 | 0.200 |
Why?
| | History, 20th Century | 1 | 2024 | 325 | 0.200 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 184 | 0.200 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 413 | 0.200 |
Why?
| | Cholesterol | 5 | 1997 | 410 | 0.200 |
Why?
| | Myocardium | 5 | 2010 | 1002 | 0.200 |
Why?
| | Anthropometry | 3 | 2011 | 213 | 0.190 |
Why?
| | Fibrinolysis | 2 | 2008 | 146 | 0.190 |
Why?
| | Kidney Diseases | 2 | 2025 | 408 | 0.190 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.190 |
Why?
| | Apoptosis | 1 | 2011 | 2553 | 0.190 |
Why?
| | Authorship | 1 | 2023 | 53 | 0.190 |
Why?
| | Supine Position | 6 | 1999 | 39 | 0.190 |
Why?
| | Cold Temperature | 7 | 2001 | 179 | 0.190 |
Why?
| | Terminology as Topic | 1 | 2023 | 216 | 0.190 |
Why?
| | Adrenal Medulla | 1 | 2002 | 9 | 0.190 |
Why?
| | Sugars | 1 | 2022 | 41 | 0.190 |
Why?
| | Respiration | 7 | 1998 | 199 | 0.190 |
Why?
| | Coronary Disease | 6 | 1998 | 385 | 0.190 |
Why?
| | Citrulline | 1 | 2022 | 45 | 0.190 |
Why?
| | Universities | 1 | 2024 | 433 | 0.180 |
Why?
| | Body Weight | 10 | 2019 | 985 | 0.180 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 178 | 0.180 |
Why?
| | Insulin | 11 | 2022 | 2409 | 0.180 |
Why?
| | Sirolimus | 3 | 2021 | 276 | 0.180 |
Why?
| | Progesterone | 1 | 2002 | 254 | 0.180 |
Why?
| | Weight Gain | 1 | 2004 | 519 | 0.180 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 55 | 0.180 |
Why?
| | Nicotine | 1 | 2023 | 334 | 0.180 |
Why?
| | Fatty Liver | 1 | 2023 | 243 | 0.180 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 88 | 0.170 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 146 | 0.170 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 121 | 0.170 |
Why?
| | Mexican Americans | 1 | 2001 | 120 | 0.170 |
Why?
| | Knee | 1 | 2000 | 68 | 0.170 |
Why?
| | DNA Methylation | 2 | 2024 | 643 | 0.160 |
Why?
| | Lipocalin-2 | 1 | 2020 | 79 | 0.160 |
Why?
| | Lung | 4 | 1999 | 4060 | 0.160 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 135 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 168 | 0.160 |
Why?
| | Triglycerides | 4 | 2017 | 524 | 0.160 |
Why?
| | RNA, Untranslated | 1 | 2021 | 124 | 0.160 |
Why?
| | Functional Food | 1 | 2019 | 2 | 0.160 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 429 | 0.160 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 39 | 0.160 |
Why?
| | Menopause | 2 | 2006 | 320 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2021 | 218 | 0.160 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 28 | 0.160 |
Why?
| | Mentors | 1 | 2021 | 202 | 0.160 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 41 | 0.160 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 390 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 49 | 0.150 |
Why?
| | Rats | 11 | 2015 | 5647 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 480 | 0.150 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 54 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 746 | 0.150 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 22 | 0.150 |
Why?
| | Social Class | 1 | 2001 | 282 | 0.150 |
Why?
| | Stroke Volume | 7 | 1998 | 612 | 0.150 |
Why?
| | Linear Models | 2 | 2012 | 849 | 0.150 |
Why?
| | Guidelines as Topic | 1 | 2020 | 275 | 0.150 |
Why?
| | Cohort Studies | 5 | 2013 | 5742 | 0.140 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 354 | 0.140 |
Why?
| | Methionine | 1 | 2018 | 160 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 274 | 0.140 |
Why?
| | Leptin | 5 | 2019 | 236 | 0.140 |
Why?
| | Adipocytes | 1 | 2019 | 222 | 0.140 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 139 | 0.140 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 59 | 0.140 |
Why?
| | Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 60 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 57 | 0.130 |
Why?
| | Stress, Psychological | 3 | 1995 | 1100 | 0.130 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4295 | 0.130 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 36 | 0.130 |
Why?
| | Heart Conduction System | 4 | 2002 | 99 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 44 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2018 | 233 | 0.130 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 110 | 0.130 |
Why?
| | Education, Graduate | 1 | 2016 | 34 | 0.130 |
Why?
| | Students, Health Occupations | 1 | 2016 | 34 | 0.130 |
Why?
| | Insulin Resistance | 3 | 2018 | 1208 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1998 | 255 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 305 | 0.120 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.120 |
Why?
| | Age Distribution | 1 | 1997 | 392 | 0.120 |
Why?
| | Walking | 3 | 2011 | 529 | 0.120 |
Why?
| | Hemostasis | 2 | 1998 | 82 | 0.120 |
Why?
| | Risk Assessment | 2 | 2018 | 3457 | 0.120 |
Why?
| | Program Development | 1 | 2018 | 364 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 341 | 0.120 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 28 | 0.120 |
Why?
| | Middle Cerebral Artery | 2 | 2025 | 53 | 0.120 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 59 | 0.120 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.120 |
Why?
| | Urinalysis | 1 | 2015 | 77 | 0.110 |
Why?
| | Sex Factors | 3 | 2025 | 2071 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 518 | 0.110 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 12 | 0.110 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 12 | 0.110 |
Why?
| | Skinfold Thickness | 4 | 1999 | 46 | 0.110 |
Why?
| | Rotenone | 1 | 2014 | 11 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 19 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 257 | 0.110 |
Why?
| | Neurons | 2 | 1995 | 1590 | 0.110 |
Why?
| | Nutritional Status | 1 | 2016 | 350 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2014 | 61 | 0.110 |
Why?
| | Plasma Volume | 3 | 2002 | 19 | 0.100 |
Why?
| | Cell Cycle | 1 | 2016 | 601 | 0.100 |
Why?
| | Liver | 3 | 2017 | 1943 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 129 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 898 | 0.100 |
Why?
| | Plethysmography | 4 | 2007 | 106 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1509 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 124 | 0.100 |
Why?
| | Epidemiology | 1 | 2013 | 33 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 131 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 307 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 67 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 259 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 259 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 12 | 0.100 |
Why?
| | Body Temperature | 5 | 1991 | 222 | 0.100 |
Why?
| | Pyrogallol | 1 | 2012 | 2 | 0.100 |
Why?
| | Hypotension | 1 | 1993 | 122 | 0.100 |
Why?
| | Mental Processes | 1 | 1992 | 32 | 0.100 |
Why?
| | Catecholamines | 5 | 1996 | 98 | 0.100 |
Why?
| | Prospective Studies | 6 | 2021 | 7604 | 0.100 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 12 | 0.100 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 121 | 0.090 |
Why?
| | Waist Circumference | 1 | 2012 | 143 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 129 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 7 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 4 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| | Myography | 1 | 2011 | 7 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 42 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 115 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 79 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 17 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2022 | 15657 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.090 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 366 | 0.090 |
Why?
| | Diastole | 3 | 2003 | 149 | 0.090 |
Why?
| | Connective Tissue | 1 | 2010 | 36 | 0.090 |
Why?
| | Endorphins | 1 | 1990 | 10 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 409 | 0.090 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.090 |
Why?
| | United States | 3 | 2020 | 14841 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.080 |
Why?
| | Caspases | 1 | 2011 | 247 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1060 | 0.080 |
Why?
| | Benzamides | 1 | 2011 | 216 | 0.080 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.080 |
Why?
| | Communication | 1 | 2016 | 879 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 338 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 77 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 133 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5131 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 253 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3196 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 992 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 83 | 0.080 |
Why?
| | Subclavian Artery | 1 | 1989 | 28 | 0.080 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 27 | 0.080 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 65 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4030 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 329 | 0.080 |
Why?
| | Acclimatization | 1 | 1990 | 177 | 0.080 |
Why?
| | Probability | 1 | 2010 | 304 | 0.080 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.080 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.080 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 157 | 0.070 |
Why?
| | Homeostasis | 3 | 2021 | 621 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 20 | 0.070 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 27 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2486 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 261 | 0.070 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 79 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 810 | 0.070 |
Why?
| | Propranolol | 4 | 2001 | 50 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 247 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 83 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 311 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 84 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 145 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 402 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 789 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 49 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 139 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 90 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1357 | 0.070 |
Why?
| | Catalase | 1 | 2007 | 130 | 0.070 |
Why?
| | Electrophysiology | 3 | 1993 | 217 | 0.070 |
Why?
| | Kinetics | 3 | 1997 | 1670 | 0.070 |
Why?
| | Telomere | 1 | 2010 | 280 | 0.060 |
Why?
| | Amidohydrolases | 1 | 2006 | 31 | 0.060 |
Why?
| | Gene Expression | 1 | 2011 | 1502 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2828 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 363 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 143 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 131 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 49 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 96 | 0.060 |
Why?
| | Codon | 1 | 2005 | 89 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 45 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 996 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 788 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 9 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 323 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 13 | 0.060 |
Why?
| | Aniline Compounds | 1 | 2025 | 102 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.060 |
Why?
| | Vital Capacity | 2 | 2000 | 311 | 0.060 |
Why?
| | Vasopressins | 1 | 2005 | 64 | 0.060 |
Why?
| | Thigh | 2 | 2003 | 48 | 0.060 |
Why?
| | Calorimetry | 1 | 2004 | 70 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1353 | 0.050 |
Why?
| | Up-Regulation | 1 | 2007 | 843 | 0.050 |
Why?
| | Osmolar Concentration | 3 | 2001 | 171 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1120 | 0.050 |
Why?
| | Postprandial Period | 1 | 2004 | 107 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2475 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 594 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2167 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1547 | 0.050 |
Why?
| | Powders | 1 | 2023 | 43 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2833 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 8 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 132 | 0.050 |
Why?
| | Biology | 1 | 2023 | 88 | 0.050 |
Why?
| | Femur | 2 | 2001 | 254 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1996 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 7 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 362 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 99 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 400 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 2 | 0.050 |
Why?
| | Phentolamine | 1 | 2001 | 15 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2691 | 0.050 |
Why?
| | Mesentery | 1 | 2002 | 48 | 0.050 |
Why?
| | Ischemia | 5 | 1994 | 409 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 36 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 59 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 600 | 0.050 |
Why?
| | Men | 1 | 2001 | 21 | 0.050 |
Why?
| | Lactic Acid | 4 | 1995 | 305 | 0.050 |
Why?
| | Genotype | 1 | 2007 | 1916 | 0.050 |
Why?
| | Sulfonamides | 1 | 2025 | 513 | 0.050 |
Why?
| | Acarbose | 1 | 2021 | 3 | 0.050 |
Why?
| | Tidal Volume | 2 | 1993 | 86 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 21 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2001 | 17 | 0.040 |
Why?
| | Models, Biological | 2 | 2004 | 1783 | 0.040 |
Why?
| | Neurons, Afferent | 2 | 1993 | 97 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1050 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 179 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 225 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 87 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 42 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 133 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2531 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 91 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 382 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 477 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 225 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 68 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 485 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 265 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2031 | 0.040 |
Why?
| | NADP | 1 | 2019 | 49 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 660 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1046 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 23 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 494 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 121 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 828 | 0.040 |
Why?
| | Prevalence | 2 | 2005 | 2734 | 0.040 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 86 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 418 | 0.030 |
Why?
| | Acute Disease | 1 | 2000 | 1007 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 82 | 0.030 |
Why?
| | Automation | 1 | 1997 | 95 | 0.030 |
Why?
| | Mathematics | 2 | 1996 | 103 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 145 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 642 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 10 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 103 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 26 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1289 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 33 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 111 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 84 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 199 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 224 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 216 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 193 | 0.030 |
Why?
| | Pain | 2 | 1992 | 756 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2844 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 203 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 11 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 128 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 52 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 43 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 23 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 319 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 24 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 61 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 81 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 203 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 298 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 5 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 293 | 0.030 |
Why?
| | Health | 1 | 2014 | 84 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3284 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 235 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 20 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 31 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2015 | 290 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 412 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 528 | 0.030 |
Why?
| | Reflex, Stretch | 1 | 1993 | 10 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 886 | 0.030 |
Why?
| | Denervation | 1 | 1993 | 24 | 0.030 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 14 | 0.030 |
Why?
| | Venous Pressure | 1 | 1992 | 8 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 51 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2013 | 81 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 762 | 0.020 |
Why?
| | Fingers | 1 | 2013 | 88 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 518 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 617 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 1995 | 289 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1993 | 332 | 0.020 |
Why?
| | Skin Temperature | 1 | 1992 | 30 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 152 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 58 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 8 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 183 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2847 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 265 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 3 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 331 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 21 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 429 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 155 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 3 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 810 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 168 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 89 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 33 | 0.020 |
Why?
| | Fever | 1 | 1990 | 306 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 133 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 342 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 8 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 169 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 31 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 43 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 4 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1092 | 0.020 |
Why?
| | Child | 3 | 1997 | 21935 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 379 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 206 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 352 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1164 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 531 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 657 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 329 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 42 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 579 | 0.020 |
Why?
| | Syncope | 1 | 1986 | 52 | 0.020 |
Why?
| | Blood Proteins | 1 | 1988 | 252 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 706 | 0.020 |
Why?
| | Feedback | 1 | 2005 | 173 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 12 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 52 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1477 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 413 | 0.010 |
Why?
| | Affect | 1 | 2007 | 292 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3015 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 105 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 163 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 333 | 0.010 |
Why?
| | Methods | 1 | 1983 | 65 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 187 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 180 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 3 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 339 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 570 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 22 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 54 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 142 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 19 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 19 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 41 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 198 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 115 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 42 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 565 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 253 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 55 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 521 | 0.010 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 101 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 94 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 61 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 159 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 319 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 8 | 0.000 |
Why?
| | Risk | 1 | 1987 | 912 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 114 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 62 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 493 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 409 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1083 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|